Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients

Abstract

Background and Objectives: Non-Alcoholic Fatty Liver Disease (NAFLD) is an emerging cause of hepatopathy that is showing an increasing trend and where the recommendations of lifestyle modification are often not sufficient. The aim of this study is to evaluate the efficacy and tolerability profile of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®) by analyzing liver enzymes, along with the lipidic profile, as markers of liver function, and ultrasound results in NAFLD patients. Materials and Methods: This study enrolled 81 patients with mild to severe NAFLD, divided into two groups: Group A (N = 41) received two capsules a day of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®), and Group B (N = 40) received only recommendations for lifestyle modification including hypocaloric diet, physical exercise and encouragement for weight loss. Patients have been evaluated at three timepoints: baseline (T0), after 45 days of treatment (T1) and after 90 days of treatment (T2), by collecting blood parameters of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and the lipid blood profile. Ultrasonographic results have been analyzed at T0 and T2, along with the tolerability profile and side effects, registered at time T2. Results: The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®) was effective since it showed a significant reduction of the evaluated parameters of ALT, AST, ALP and GGT, a significant improvement of lipid parameters, evaluated as markers of liver function, and improvements of ultrasonographic results. The use of this formulation at the dosage of two capsules a day has been well tolerated and no adverse events have been reported during study period of three months. Conclusions: The administration of the association of silymarin, vitamin C, vitamin E, coenzyme Q10 and selenomethionine (Medronys epato®) was effective and well tolerated in the improvement of hepatic function of NAFLD patients.

Silymarin: Unveiling its pharmacological spectrum and therapeutic potential in liver diseases—A comprehensive narrative review

“…Understanding these molecular mechanisms can provide a scientific foundation for exploring innovative therapeutic approaches, offering hope for more effective and sustainable strategies in mitigating NAFLD progression, especially in cases where conventional lifestyle changes are challenging (Drescher et al, 2019;Tarantino et al, 2019;Younossi & Henry, 2022). herence to lifestyle changes (Curcio et al, 2020;Handayani & Prijanti, 2024).…”

A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases

“…For instance, along with the Mediterranean diet, twice-daily administration of silymarin (210 mg) for 6 months has led to significant improvement in the glycemic profile and regression of liver damage (Colletta et al, [ 111 ]). Silymarin, vitamin C, vitamin E, and coenzyme Q10 and selenomethionine (Medronys epato®) contain a capsule twice a day for 45- and 90-days treatments that has histologically improved liver function and reduced the marker enzymes of liver toxicity (ALT, AST, ALP, and GGT) and lipid markers (total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and TG) in serum of NAFLD patients (Curcio et al, [ 112 ]). In another study, treatment with silymarin (Eurosil 85®) and α -tocopherol (MEDAS SL) along with a low-calorie diet (1520 kcal) with exercise for three months significantly reduced ALT and AST activities and improved liver function in NAFLD patients (Aller et al, [ 113 ]).…”

A Double-Pronged Sword: XJB-5-131 Is a Suppressor of Somatic Instability and Toxicity in Huntington’s Disease

“…other neurological manifestations, suggesting that an tissue specific [39,[42][43][44][45][46]. For example, MitoQ, a mitochondrial-targeted CoQ 10 derivative, failed to offset neurodegeneration in PD clinical trials, but has shown unexpected promise in the periphery, as a therapeutic in treating non-alcoholic fatty liver disease [47,48].…”